Its pipeline and development offerings have been previously validated via collaborations with Abbvie’s ImmunoGen, Zymeworks and Boehringer Ingelheim, among others. "Oxford BioTherapeutics and Roche ...

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody drug conjugate (ADC)-based therapies, announced a multi-year collaboration with ...

Oxford BioTherapeutics (OBT ... antibodies arising from the collaboration make it to market. According to its pipeline listing, the Roche alliance covers some 12 separate programmes.

Roche has secured its third antibody-drug conjugate pact of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics. The agreement will also see U.K.-based ...

(MENAFN- EIN Presswire) Partnership to accelerate development of Novel Small Extracellular Vesicle CNS Drug Delivery Platform and enhance Interactome Biotherapeutics' Pipeline OXFORD , UNITED ...

OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc ... TI is poised to drive multiple future pipeline and partnership opportunities ...

Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based therapeutics for cancer. The multi-year collaboration combines Roche’s drug ...

Oxford Biotherapeutics Ltd. is partnering with Roche AG to expand the current field of tumor antigens that can be drugged with antibodies, as part of a potential $1 billion-plus agreement. The ...